TGF-β gene polymorphisms as risk factors for asthma control among clinic patients.

Michał Gabriel Panek (michal.panek@pta.med.pl)
Uniwersytet Medyczny w Łodzi  https://orcid.org/0000-0002-3718-4793

Konrad Stawiski
Uniwersytet Medyczny w Łodzi

Piotr Bolesław Kuna
Uniwersytet Medyczny w Łodzi

Research article

Keywords: asthma, TGFβ1, TGFβ2 and TGFβ3 gene, SNPs, inflammation, asthma control, the Asthma Control Test (ACTTM)

Posted Date: May 15th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-26054/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background:

TGF-β and its receptors play a key role in asthma pathogenesis, bronchial hyperreactivity and bronchial remodeling. Expression of isoforms 1–3 of TGFβ cytokine is influenced by tagging polymorphisms in the TGFβ1, TGFβ2 and TGFβ3 gene, and these SNPs may be associated with the risk of asthma development and severity as well as with other diseases. Polymorphic forms of TGF-β1, TGF-β2 and TGF-β3 genes regulate the degree of bronchial inflammation, deterioration of lung functional parameters in spirometry and elevated level of total IgE. All this results in intensification of disease symptoms. According to current GINA 2020 guidelines, the Asthma Control Test (ACT™) should be applied to assess asthma symptoms.

Methods:

An analysis of polymorphisms localized in TGF-β1, TGF-β2 and TGF-β3 genes was conducted on 652 DNA samples with an application of the MassARRAY® system using the mass spectrometry technique MALDI TOF MS. The degree of asthma control was evaluated with ACT™.

Results:

The occurrence of the T / C genotype in rs8109627 (p = 0.0171) in the TGF-β1 gene is significantly associated with a higher ACT result (controlled asthma) in a multivariate linear regression analysis model after using backward stepwise selection of variables. In addition, in the linear model for prediction of ACT score we showed SNP rs8109627 (p = 0.0497) in the TGF-β1 gene (improvement of the disease control - controlled asthma) and rs2796822 (p = 0.0454) in the TGF-β2 gene (deterioration of the diseases control - uncontrolled asthma) significantly modify the degree of asthma control.

Discussion:

We described clinical significance of two SNPs in two genes TGF-β1 and TGF-β2, as yet unknown. We proved that the use of both genotypes and MAC allows to create a moderately correct prognostic model which is about 70% efficient on the entire set of analyzed SNPs in TGF-β1, TGF-β2, and TGF-β3 genes.

Background

Asthma is a chronic, inflammatory and heterogeneous respiratory disease. Many genes, inflammatory cells and substances secreted by them are involved in the etiopathogenesis of this disease. The clinical picture depends on complex gene-gene and gene-environment interactions. These components make asthma a dynamic disease, and its classifications can change both during treatment and irrespective of it. The etiology of bronchial asthma is multifactorial. The disease develops under the influence of
variables, which, according to the report of the *Global Strategy for Asthma Management and Prevention* (GINA) can be divided into those which induce asthma and those which trigger its clinical symptoms. According to current GINA 2019 guidelines, the Asthma Control Questionnaire (ACQ) or the Asthma Control Test (ACT) can be used to assess its symptoms. The severity of the disease is assessed not on the basis of the intensity of symptoms before the treatment is initiated, but only after several months of the treatment, when the level of intensity, necessary to achieve and maintain asthma control, has been established [1,2,3,4]. TGF-β (transforming growth factor β) is the most important gene responsible for bronchial hyperreactivity and development of structural changes in bronchial walls is [5,6,7,8]. The key role of TGF-β as a growth factor responsible for prolonged reparatory processes and activation of myofibroblasts has been demonstrated in many studies on airway inflammation and its bronchial remodeling in asthma [5,6,7,8,9,10,11,12]. Increased TGFβ expression has been observed in asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, systemic scleroderma, non-alcoholic steatohepatitis, renal failure, myocardial infarction, or heart failure. It should be mentioned here that deregulation of TGFβ cell signaling homeostasis is the main mechanism initiating and regulating the progression of fibrosis in various tissues. TGFβ is a pleiotropic cytokine that regulates cell proliferation, contributes to epithelial-to-mesenchymal transition (EMT), suppresses the function of immune cells compromising immune response, contributes to the conversion of fibroblasts to myofibroblasts and causes overproduction of extracellular matrix (ECM) in tissues undergoing fibrosis. TGFβ upregulates expression and synthesis of many matrix proteins, primarily through recruitment of myofibroblasts. Proteins upregulated by TGFβ include collagens I - V, basement membrane proteins (laminin, entactin, perlecan) and ECM proteins (fibronectin, osteopontin, thrombospondin, tenascin, osteonectin/SPARC, elastin, biglycan, decorin, and hyaluronan). Additionally, at early stages of fibrosis, TGFβ stimulates myofibroblasts and other stromal cells to enhance the synthesis of collagen crosslinking enzymes, particularly lysyl oxidase, which increases the rigidity of the collagen network. Moreover, TGFβ downregulates the synthesis of matrix-depleting proteins, such as matrix metalloproteinases (MMP-1, -8, -13). As a result, the increase in matrix protein synthesis and decrease in matrix proteinase activity, owing to the TGF β activity, contribute to the remodeling of the bronchial ECM and can result in a fibrotic response [11,12,13,14,15,16]. Polymorphic forms of the TGFβ gene can significantly contribute to the development of asthma, induce disease progression and its complications, and have a significant clinical impact on symptom control. Single Nucleotide Polymorphism (SNP) rs8179181 in the TGFβ1 gene induces development of childhood asthma and atopy. It increases the risk of a severe course of the disease and correlates with high levels of TGFβ1 mRNA [17]. rs4803455 has been reported to increase the risk of asthma development. This SNP down-regulates the lung function and induces airway remodeling in asthma [18]. rs1800469 in the TGF-β1 gene promoter increases the plasma level of TGF-β1 and the level of total IgE. It may also reduce the risk of progression of bronchial remodeling as well as inhibit the development of asthma [19,20,21,22]. rs11083616 correlates with bronchial obstruction and with airway wall phenotypes - airway wall thickness. The presented SNP is an important marker of the development of all obstructive diseases [23]. The role of rs8109627 in the TGFβ1 gene has not been explicitly and precisely described in the etiopathogenesis of asthma. SNPs tagging in the TGFβ2 gene (rs10495098, rs17047703, rs17558745, rs2799085, rs2009112, rs10482751, rs2027567,
rs10779329, rs2796821, rs2796822, rs4846479, rs2798631, rs10863399) and the TGFβ3 gene (rs4903359, rs3917187, rs2284792, rs2268626) have not been analyzed as risk factors for development of obstructive diseases [24]. Table 1 presents detailed characteristics of TGFβ1, TGFβ2 and TGFβ3 genes and their SNPs.

Table 1. Presentation of SNPs TGFβ genes on the base of the NCBI gene database, available on:

| Name/Gene ID | Description | Location | Aliases | MIM | SNPs |
|--------------|-------------|----------|---------|-----|------|
| TGFB1 ID: 7040 | transforming growth factor beta 1 [Homo sapiens (human)] | Chromosome 19, NC_000019.10 (41330323..41353922, complement) | CED, DPD1, IBDIMDE, LAP, TGF-beta1, TGFB, TGFbeta | 190180 | rs8109627, rs8179181, rs4803455, rs1800469, rs11083616 |
| TGFB2 ID: 7042 | transforming growth factor beta 2 [Homo sapiens (human)] | Chromosome 1, NC_000001.11 (218345284..218444619) | G-TSF, LDS4, TGF-beta2 | 190220 | rs10495098, rs17047703, rs17558745, rs2799085, rs2009112, rs10482751, rs2027567, rs10779329, rs2796821, rs2796822, rs4846479, rs2798631, rs10863399 |
| TGFB3 ID: 7043 | transforming growth factor beta 3 [Homo sapiens (human)] | Chromosome 14, NC_000014.9 (75958061..75983011, complement) | ARVD, ARVD1, LDS5, RNHF, TGF-beta3 | 190230 | rs4903359, rs3917187, rs2284792, rs2268626 |

https://www.ncbi.nlm.nih.gov/gene/?term=TGFB1,
https://www.ncbi.nlm.nih.gov/gene/?term=TGFB2,
https://www.ncbi.nlm.nih.gov/gene/?term=TGFB3

Aims

Our purpose was to determine whether genotypes of MAC/SNP TGFβ1, TGFβ2 and TGFβ3 are related to the level of asthma control, measured with the application of the Asthma Control Test (ACT™) in asthmatics and healthy controls.

Methods

Consent of the Bioethics Committee

The study was approved by the local ethics committee (Consent of Research Review Board at the Medical University of Lodz, Poland, No RNN/133/09/KE). At the commencement of the study, the participants were invited to get involved voluntarily. Before the enrolment, a written informed consent was obtained from each patient.

Subjects

Asthma diagnosis was established according to GINA (The Global Initiative For Asthma) recommendations, based on clinical asthma symptoms and a lung function test. The level of asthma
severity and control was determined on the basis of the GINA Report Guidelines. All the participants underwent subjective examinations (structuralized anamnesis including, besides the element of subjective examination, also an analysis of factors such as: gender, obesity, tobacco smoking, duration of bronchial asthma, allergy to house dust mites, animal fur, mould spores, cockroaches allergens, hypersensitivity to non-steroid anti-inflammatory drugs (NSAIDs), etc. Results of pulmonary function tests and allergologic tests were obtained from individual medical records of the patients. If results of spirometry or allergological tests were not available, such examinations were additionally performed during the recruitment visit. Subjects suffering from clinically significant exacerbations and using drugs which might induce resistance to glucocorticoids (such as rifampicin, phenobarbital, phenytoin, ephedrine), subjects with signs of viral infections, either generalized, or affecting the respiratory tract, as well as subjects failing to comply with the doctor’s recommendations, were excluded from the patient group. The control arm included a group of healthy adults who met the following criteria: no history or symptoms of either bronchial asthma, or other pulmonary diseases, no history or symptoms of allergy, no history or symptoms of atopic dermatitis, no history or signs of hypersensitivity to aspirin, negative results of skin tests for 12 common allergens, no first-degree relatives with bronchial asthma or atopic disorders. Spirometry tests were conducted in the Outpatient Clinic according to ERS (European Respiratory Society)/ATS (American Thoracic Society) standards, and allergological tests according to EAACI (European Academy of Allergy and Clinical Immunology) guidelines [19,20,21,22,25,26,27].

Note: The authors of the article for this scientific project used their own patient database containing detailed statistical and genetic characteristics, used in previous publications. However, in this manuscript, they do not present results published earlier in any other study (the article contains original results not published elsewhere).

652 subjects were included in the study. Of this number, there were 345 asthmatic patients at the average age of 48.6 years, and 307 healthy subjects at the average age of 46.0 years. Detailed patients' characteristics were presented in Table 2.

Table 2. Clinical characteristics of the recruited cohort and spirometric characteristics of the studied groups.

| Characteristics of the studied groups | Asthmatic Patients (n=345) | Healthy Controls (n=307) | p-value |
|--------------------------------------|---------------------------|--------------------------|---------|
| Age [years]                          | 48.6±15.4                 | 46.0±16.3                | 0.04    |
| Sex                                  | Females: 222 Males: 123   | Females: 197 Males: 110  | 0.96    |
| FEV1(%)                              | 75.81±21.37               | 95.83±19.95              | <0.001  |
| FVC(%)                               | 93.52±18.78               | 101.63±17.69             | <0.001  |
| FEV1/FVC(%)                          | 83.25±14.71               | 95.88±10.05              | <0.001  |
| Smoking pack years                   | 5.82±10.98                | 5.68±11.71               | 0.88    |
FEV1 (forced expiratory volume in 1 second) expressed in %, FEV1% (A/N% - percentage ratio of the measured to expected value) expressed as per cent of the expected value; FVC (forced vital capacity) expressed in %, FVC% (A/N% - percentage ratio of the measured to expected value) expressed as per cent of the expected value; FEV1% FVC index (FEV1 to FVC ratio - forced vital capacity) expressed in %.

The whole group of patients participating in the study was stratified and subjected to a statistical analysis. The genotyping was performed by two investigators who were unaware of the phenotypes.

Genomic DNA extraction and SNPs analysis (MassARRAY ® system)

Venous blood samples were collected from the participants onto EDTAK3, and DNA was obtained from peripheral blood leukocyte fraction. The genetic material was isolated using QIAamp DNA Blood Mini Kit (QIAGEN Inc.) according to guidelines provided by the manufacturer (12,13,17,18,19).

An analysis of polymorphisms localized in TGF-β1, TGF-β2 and TGF-β3 genes was conducted on 652 DNA samples with the application of the MassARRAY® system (Bionanopark, Lodz, Poland), using the mass spectrometry technique (MALDI TOF MS – matrix-assisted laser desorption ionization–time-of-flight mass spectrometry), dedicated to nucleic acids.

The authors measured the output level of genomic human DNA and diluted DNA to obtain final cDNA levels = 15 [ng/µl]. In samples with the DNA level lower than 15 [ng/µ], a sufficient undiluted amount of sample was used for analytical purposes. The absorbance ratio A260/A280, identified as a degree of DNA impurities, ranged from 1.7 to 2.0. The DNA levels were measured in all the studied samples.

The first stage of laboratory tests involved performing multiplex-PCR, specific for particular loci, in which 20 fragments of DNA, around 100 bp (base pairs) long, were amplified. Each DNA fragment had a polymorphic locus in its sequences.

After performing PCR, the remaining unbound dNTPs were dephosphorylated using Shrimp Alkaline Phosphatase (SAP).

Next stage involved performing iPLEX reaction. On the matrix which was formed during the multiplex-PCR reaction, terminal dideoxynucleotides (ddNTPs), corresponding to the allele variant present in the gene, were bonded to MassEXTEND primers with modified mass and complementary to the sequence, located above the polymorphic locus.

After performing the iPLEX reaction, 15 mg resin was placed on each well of a 96-well plate to bind metal ions, such as Na+, K+, Mg2+, which might cause high background interferences in mass spectra. After centrifugation of the plate (5 min., 4000 rpm), the analyzed material was transferred to SpectroCHIP with the use of Nanodispenser RS1000. Its volume ranged from 3 to 25 nl and bonded with the agent filling each of the 96 wells on the chip.

The first stage of the mass spectrometer analysis included matrix laser desorption, needed for a DNA analysis. SpectroCHIP is placed inside the spectrometer, and each place with a DNA sample is ionized
with a laser in the vacuum. An energy beam used in laser ionization must be well adjusted so that the particles do not get fragmented but bounced only. Next, the particles proceed to a time-of-flight analyzer. The particles going to the analyzer are accelerated with an electric impulse and start drifting through the analyzer chamber. At the end of the analyzer, there is an ion detector connected with a device which registers the time between the moment of acceleration impulse and the moment the particle hits the detector. A result of the mass-to-charge ratio value corresponds to a value we obtain if we follow a low of physics saying that for an impulse of particular amperage, the time-of-flight of ions gets longer if their molecular weight increases. An analysis of sample using the MassARRAY mass spectrometer enabled to obtain raw results which were presented in the form of mass spectra. The mass spectra in turn, allowed to identify polymorphisms in the following studied genes: TGF-β1, TGF-β2 and TGF-β3. The graphs can enable to determine reaction yield and probability of the obtained results.

Statistical analysis

The Kruskal-Wallis rank sum test was applied to compare scores of asthma control test in genotypes, whereas the two-sample Wilcoxon test was used to compare the scores in minor allele carriers (MAC). Due to a large number of comparisons, the p-values were adjusted using the Benjamini & Hochberg procedure. Treating ACT score as continuous, linear regression models were developed for both genotypes and MAC statuses in order to assess the influence of variables on the ACT score. Backward stepwise selection was based on the Akaike Information Criterion for a fitted parametric model. The overall performance of the models was assessed utilizing multiple R2 and RMSE, while the influence of particular factors required a calculation of standardized beta coefficients after estimating them using standard deviation. The response variable (ACT score), although measured on a continuous scale, can be treated as an ordinal variable. Below I check whether the application of ordinal regression (i.e. proportional odds logistic regression) would bring about any changes. In order to test whether the genotypes or MAC statuses will allow to predict good asthma control (ACT ≥ 25), the logistic regression was designed in the same manner. The analysis was performed in STATISTICA 13.1 (Dell, USA) and R programming language (packages: rms, cutopointr, caret).

Results

Whole genotypes and MACs were tested in TGF-β1, TGF-β2 and TGF-β3 genes. The authors assessed their correlation with the degree of asthma control. It was found that the median of the Asthma Control Test (ACT, score in points) did not differ on genotypes of selected SNPs (p > 0.05 for all comparisons, BH correction, Bonferroni-Hochberg correction). Details are shown in Figs. 1 and 1A.

Boxplots showing differences in the median ACT score between genotypes in selected SNPs. A detailed analysis of SNPs of TGF-β1, TGF-β2 and TGF-β3 genes potentially affecting the level of asthma control using the Kruskal-Wallis Test, p with BH correction. p - level of statistical significance. BH - Bonferroni-Hochberg correction. The authors’ own study.
After using correction for multiple comparisons, the median ACT did not differ depending on the minority allele carrier (MAC) of selected SNPs ($p > 0.05$ for all comparisons, BH correction). Details are shown in Figs. 2 and 2A.

Coefficients of the linear model for prediction of ACT score. A detailed analysis of MAC in SNPs of TGF-β1, TGF-β2 and TGF-β3 genes potentially affecting the level of asthma control using the U Mann-Whitney Test, with BH correction. $p$ - level of statistical significance. BH - Bonferroni-Hochberg correction. The authors' own study.

For prediction of ACT based on genotype, the full model without feature selection showed low $R^2$, equal to 0.084 and RMSE equal to 5.47 points. After applying the backward stepwise procedure, rs8109627, rs2799085, rs3917187 and rs2284792 were the only remaining SNPs in the model. Despite the feature selection, the $R^2$ did not improve and was equal to 0.05 with RMSE equal to 5.57 points. The model is shown on Fig. 2A.

The greatest standardized beta coefficient, thus the greatest influence on predicted ACT, was shown for genotype G/G rs2284792; however, this was not significant in the t-test ($p = 0.06$). T/C genotype in rs8109627 was the only statistically significant variable in the t-test, associated with linear modeling. It is further shown in calibration plot. See Fig. 2B.

Calibration plot showing a relationship between predicted and actual results in the ACT score. Although the correlation is significant, the rho coefficient does not prove a strong relationship.

In a similar analysis, but involving MAC, the final model after feature selection revealed that rs8109627, rs2796822 and rs2798631 are most important. The multiple $R^2$ was, however, low and equal to 0.02 with RMSE equal to 5.66 points. The estimates are shown in Table 3.

Table 3. Coefficients of the linear model for prediction of the ACT score. The MAC status was considered interesting. Although rs8109627 and rs2796822 show significant association with the ACT score, the effect seems too slight.

| SNP tested   | Beta estimate | Standardized beta | Standard Error | P-value  |
|--------------|---------------|-------------------|----------------|----------|
| rs8109627    | 1.1115        | 0.0957            | 0.5646         | 0.0497*  |
| rs2796822    | -1.7930       | -0.1534           | 0.8932         | 0.0454*  |
| rs2798631    | 1.3661        | 0.1123            | 0.9293         | 0.1423   |

Predictive analysis of the ACT result, depending on the genotypes of the studied SNPs with the application of backward selection, showed that the occurrence of the T / C genotype in rs8109627 is significantly associated with a higher ACT result (standardized beta = 0.11). In general, despite the variable selection, the model was characterized by low efficiency (adjusted $R^2$ 0.03). A GVIF analysis also showed that the model could have been characterized with collinearity of variables. Details are presented in Fig. 3.
Multivariate linear regression analysis after stepwise backward selection of variables, describing the effect of the studied SNPs genotypes on the level of asthma control (ACT). The authors’ own study.

Considering only the MAC analysis, in multivariate linear regression analysis, after applying stepwise backward selection of variables, the authors managed to reveal that MAC in rs8109627 is significantly associated with a higher ACT result (better asthma control), and in rs2796822 with a lower ACT result (worse asthma control). The selection of variables showed that MAC is most important in rs8109627, rs2796822 and rs2798631. However, the model was characterized with low efficiency (adjusted R2 0.01). Details of the analysis are presented in Fig. 4.

Analysis of ACT result prediction, depending on MAC SNPs (full analysis model including all SNPs). The authors’ own study.

The authors made an attempt to create a decision tree (ctree), allowing to prognosticate the degree of disease control in ACT, based on particular SNPs in the studied genes. An attempt to model trees appeared to be unsuccessful in this case. The authors did not manage to obtain results which would be more resistant to over-adjusting after application of other techniques (e.g. ctree - decision trees), as illustrated in Fig. 5.

Modeling the ctree, allowing to prognosticate the degree of asthma control, on the basis of SNPs analysis of TGF-β1, TGF-β2 and TGF-β3 genes. The authors’ own study.

An analysis of ROC curves showed that statistical modeling may be useful in clinical practice. Good asthma control could be predicted by analyzing all twenty SNPs and not by analyzing MAC results in SNPs. These observations are illustrated in Fig. 6.

An analysis of prognosis of effective asthma control (ACT ≥ 25) on the basis of ROC analysis. A Logistic regression with the application of all genotypes in SNPs contributed to AUC = 0.749. B Logistic regression with the application of all MACs in SNPs contributed to AUC = 0.661. The authors’ own study.

Due to the class imbalance, better results were obtained after performing the SMOTE-type modeling. Predicting good asthma control (ACT ≥ 25) with the use of this method enables to achieve 86.11% specificity and 49.17% sensitivity. Results are shown in Fig. 7.

A SMOTE analysis and analysis with the application of backward stepwise selection, enabling to predict good asthma control (ACT ≥ 25), on the basis of all twenty SNPs. The authors’ own study.

Predicting good asthma control is possible with the SMOTE method. It should be noted that both the use of genotypes and MAC allows to create a moderately correct prognostic model which is about 70% efficient on the entire (training) data set. The description is shown in Fig. 8.

An analysis of the application of a prognostic model on the basis of SNP and MAC genotypes on the entire (training) data set for the purpose of prediction of good asthma control. The authors’ own study.
Discussion

The role of polymorphic forms of genes in asthma, especially single ones, has been widely discussed for years in international professional literature [12,13,19,20,21,22]. Our work, unlike many others, presents a holistic and unique analysis along with a detailed statistical methodology that allows us to assess the effect of twenty SNPs, simultaneously in TGF-β1, TGF-β2 and TGF-β3 genes on the degree of asthma control. Our results are also an attempt to present various statistical approaches to the problem analysis and interpretation of the said problem. The work is unique in this respect [28, 29].

Firstly, we did not note significantly different medians in ACT in genotypes and MACs (adjusted p-value >0.05 for all comparisons). See Figures: 1 and 1A. For prediction of ACT, based on the genotypes, the full model without feature selection showed low R2 equal to 0.084 and RMSE equal to 5.47 points. After application of the backward stepwise procedure, rs8109627, rs2799085, rs3917187 and rs2284792 were the only remaining SNPs in the model. Despite feature selection, the R2 did not improve and was equal to 0.05 with RMSE equal to 5.57 points. See Figures: 2 and 2A. The greatest standardized beta coefficient, thus the greatest influence on predicted ACT, was shown for genotype G/G rs2284792; however, this was not significant in the t-test (p=0.06). See Figure 2A. The only variable which was statistically significant in the t-test and associated with linear modeling, was T/C genotype in rs8109627. It is further shown in calibration plot. See Figure 2B. In a similar analysis, but involving MAC, the final model after feature selection revealed that rs8109627, rs2796822 and rs2798631 are most important. The multiple R2 was, however, low and equal to 0.02 with RMSE equal to 5.66 points. The estimates are shown in Table 3.

Next, in order to check whether the genotypes or MAC statuses will allow to predict good asthma control (ACT≥25), the logistic regression was designed in the same manner. The analysis allowed us to conclude that after performing the feature selection, the final model included only rs8109627 and rs17047703 [28,29]. See Supplementary File No 1.

It is difficult to discuss the issues described above because currently available databases (e.g. https://www.ncbi.nlm.nih.gov/pubmed/?term=SNP+TGF+asthma+control) do not have analyses of polymorphic forms of TGF-β1, TGF-β2 and TGF-β3 genes which influence the degree of asthma control. It also shows the unique nature of our work. Although literature reports an impact of single SNPs on the clinical course of asthma, there are no studies on the association between the TGF-β gene and the control of asthma symptoms [12,13,19,20,22].

Secondly, we examined the possibilities of assessing correlations with polymorphic forms of TGF-β genes using various statistical methods. We showed that in the multivariate linear regression analysis model, after using backward stepwise selection of variables, the occurrence of the T/C genotype in rs8109627 is significantly associated with a higher ACT score; however, this effect is not spectacular (beta standardized = 0.11). It should be pointed out here that it has not been well documented that this rs8109627 in the TGFβ1 gene plays a role in increasing the risk of asthma. We obtained slightly different results after analyzing not SNP, but MAC in TGF-β genes. The multivariate linear regression analysis of MAC, after backward stepwise selection of variables, showed that MAC in rs8109627 is significantly
associated with a higher ACT™ result, and in rs2796822 - with a lower one. What is interesting is the fact that this rs2796822 in the TGF-β2 gene occurs with different frequencies [1.71 (1.07,2.71) p = 0.022] in patients with non-severe and severe asthma. The risk of severe asthma in MAC carriers for the above-mentioned SNP was 71% higher (the author's data in the course of the publication procedure). A further selection of variables confirmed that MAC is most important in rs8109627, rs2796822 and rs2798631, but this model was characterized with low efficiency (adjusted R2 = 0.01). SNPs rs8109627 and rs2798631 correlated with a clinically significant higher level of asthma control (controlled asthma) in the ACT™ Test, whereas rs2796822 was associated with a lower result (loss of disease control). See Figure 2B. Nevertheless, this is the first report about the role of these three tagging SNPs in asthma, in TGF-β1, TGF-β2 and TGF-β3 genes. Details of this analysis are presented in Table 3. Despite the use of over-adjusting techniques, the authors did not manage to apply a proper ctree in the statistical analysis (ctree, see Figure 5). An attempt to optimize the prediction of good asthma control was also made (ACT> = 25). Due to the class imbalance, better results were obtained after performing the SMOTE-type modeling than after the application of multivariate linear regression analysis. For details, see Figures 6, 7 and 8.

Conducting an analysis using various statistical models enables to use both genotypes and MAC, which allows to create a moderately correct prognostic model that is about 70% efficient on the entire (training) data set (Figure 8).

In Supplementary File No 1 we checked whether the genotypes or MAC statuses will allow to predict good asthma control (ACT≥ 25); the logistic regression was designed in the same manner. The conducted procedure allowed us to conclude that after feature selection, the final model included only rs8109627 and rs17047703. See Supplementary File No 1. The role of tagging SNP rs8109627 in the TGF-β1 gene and rs17047703 in TGF-β2 had not yet been described. We were the first in the above analysis to test it with advanced statistical methods [28, 29].

In our work, we analyzed twenty tagging SNPs in TGF-β1, TGF-β2 and TGF-β3 genes. We critically interpreted the results with statistically different methods. It should be noted that only three SNPs, such as rs8109627, rs2796822 and rs2284792, play a significant clinical role in the regulation of asthma control. This is an important discovery since the role of these SNPs in the TGF-β gene in asthma had not been previously described. It should be critically stated that the prognostic efficiency of different statistical models was up to 70%. Nevertheless, the work, not carried out before, is a unique and holistic analysis of twenty polymorphic forms in TGF-β1, TGF-β2 and TGF-β3 genes using state-of-the-art techniques of molecular biology (MassARRAY® system).

**Limitations**

Both the use of genotypes and MAC allows to create only a moderately efficient prognostic model. In the multivariate linear regression analysis, after using backward stepwise selection of variables, we managed to show that only single genotypes significantly correlated with higher ACT results. However, this effect was not spectacular. In general, despite the variable selection, the efficiency of the model was still low. A GVIF analysis also showed that the model could have been characterized with collinearity of variables.
Moreover, the selection of variables showed that MAC was most important in three SNPs, but this model was not also highly efficient. The authors did not manage to obtain results which would be more resistant to over-adjusting with the application of other techniques (e.g. ctree - decision trees). Due to the class imbalance, better results were obtained after performing the SMOTE-type modeling. After performing the SMOTE-type modeling, the logistic regression model was trained on the whole dataset. Those results are vastly inflated by the application of SMOTE. By creating new cases that are similar to the original ones, the performance was only minimally inflated. According to the authors of the above statistical analyses, linear regression models are the only ones that can be used in this type of scientific studies. A small size of the surveyed populations is another limitation of the study. It would be advisable to verify our theses on subpopulations consisting of about 1000 respondents. Our results should be treated as preliminary.

Conclusion

This study is the first one ever conducted in the Polish population. It is an attempt to analyze the functional impact of twenty SNPs of TGF-β1, TGF-β2 and TGF-β3 genes on the degree of asthma control, assessed with the use of the international ACT™ Questionnaire. We showed new relationships between the occurrence of SNP rs8109627 in the TGF-β1 gene (improved disease control - controlled asthma) and rs2796822 in the TGF-β2 gene (worsened disease control - uncontrolled asthma) and a significantly changed level of asthma control. This is a particularly important observation because the TGF-β gene affects eosinophil levels, bronchial hyperreactivity and obstruction, and clinical signs of asthma. In contrast, the TGF-β1–3 gene complex is an important regulator of the immune response in asthma. We also proposed a new statistical analysis model (multivariate linear regression analysis with backward stepwise selection of variables and the SMOTE model) to assess the effect of many SNPs, simultaneously in three TGF-β genes, on disease control. The analyzed results and methods were a subject of our internal discussion during which we identified those that may be clinically useful. The presented results constitute an innovative approach to understanding the importance of SNP forms in TGF-β1, TGF-β2 and TGF-β3 genes in the regulation of asthma control.

Declarations

a. Ethics approval and consent to participate

The study was approved by the local ethics committee (Consent of Research Review Board at the Medical University of Lodz, Poland, No RNN/133/09/KE). At the commencement of the study, the participants were invited to get involved voluntarily. Before the enrolment, a written informed consent was obtained from each patient.

b. Consent for publication

Prof. Piotr Bolesław Kuna, M.D., Ph.D. – Head of Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, PL
c. Availability of data and materials

All data and materials are presented in the section of article. The authors will always provide other indicated data on request.

d. Competing interests

The authors declare that there is no conflict of interest regarding the publication of this article.

e. Funding

The study is financed from a grant of Polpharm Scientific Foundation, No 16/XIV/2015, Poland.

f. Authors’ contributions

M.P. conceived and planned the experiments. M.P. carried out the experiments. K.S. and M.P. planned and carried out the simulations. M.P. and K.S. contributed to sample preparation. M.P. and K.S. contributed to the interpretation of the results. M.P. took the lead in writing the manuscript. All authors provided critical feedback and helped shape the research, analysis and manuscript.

g. Acknowledgements

Not applicable.

h. Authors' information (optional)

List of abbreviations – abbreviations are used in the text.

References

1. 2019 GINA Main Report dostępny na https://ginasthma.org/
2. Droszcz W, Grzanka A. Asthma in adolescents and adults. Wydawnictwo Lekarskie PZWL; Warszawa: 2010.
3. Genuneit J, Cantelmo JL, Weinmayr G, Wong GW, Cooper PJ, Riikjärv MA, Gotua M, Kabesch M, von Mutius E, Forastiere F, Crane J, Nystad W, El-Sharif N, Batllés-Garrido J, García-Marcos L, García-Hernández G, Morales-Suarez-Varela M, Nilsson L, Bråbäck L, Saraçlar Y, Weiland SK, Cookson WO, Strachan D, Moffatt MF ISAAC Phase 2 Study Group. A multi-centre study of candidate genes for wheeze and allergy: the International Study of Asthma and Allergies in Childhood Phase 2. Clin Exp Allergy. 2009;39:1875–1888.
4. Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease. Lancet. 2008;372:1107–1119.
5. Djukanović R, Roche WR, Wilson JW, Beasley CR, Twentyman OP, Howarth RH, Holgate ST. Mucosal inflammation in asthma. Am Rev Respir Dis. 1990;142:434–457.
6. Sumi Y, Hamid Q. Airway remodeling in asthma. Allergol Int. 2007;56:341–348.

7. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both? Immunology. 2004;112:352–363.

8. Wang J, Young IG. Eosinophilic inflammation: mechanisms regulating IL-5 transcription in human T lymphocytes. Allergy. 2007;62:1131–1138.

9. Yang YC, Zhang N, Van Crombruggen K, Hu GH, Hong SL, Bachert C. Transforming growth factor-beta1 in inflammatory airway disease: a key for understanding inflammation and remodeling. Allergy. 2012;67:1193–1202.

10. Duvernelle C, Freund V, Frossard N. Transforming growth factor-beta and its role in asthma. Pulm Pharmacol Ther. 2003;16:181–196.

11. Park HK, Park HW, Jeon SG, Shin ES, Gho YS, Cho SH, Kim YY, Kim YK. Distinct association of genetic variations of vascular endothelial growth factor, transforming growth factor-β, and fibroblast growth factor receptors with atopy and airway hyperresponsiveness. Allergy. 2008;63:447–453.

12. Panek M, Pietras T, Fabijan A, Zioło J, Wieteska L, Małachowska B, Fendler W, Szemraj J, Kuna P. Identification and association of the single nucleotide polymorphisms, C-509T, C+466T and T+869C, of the TGF-β1 gene in patients with asthma and their influence on the mRNA expression level of TGF-β1. Int J Mol Med. 2014 Oct;34(4):975-86.

13. Koćwin M, Jonakowski M, Przemęcka M, Zioło J, Panek M, Kuna P. The role of the TGF-SMAD signalling pathway in the etiopathogenesis of severe asthma. Adv Respir Med. 2016;84(5):290-301.

14. Heldin C, Aristidis Moustakas A. Signaling Receptors for TGF-β Family Members. Cold Spring Harb Perspect Biol. 2016;1;8(8).

15. Huang T, Hinck A. Production, Isolation, and Structural Analysis of Ligands and Receptors of the TGF-β Superfamily. Methods Mol Biol. 2016;1344:63-92.

16. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 2014 Dec; 15(12): 786–801.

17. Li H, Romieu I, Wu H, Siena-Monge JJ, Ramírez-Aguilar M, del Río-Navarro BE, del Lara-Sánchez IC, Kistner EO, Gjessing HK, London SJ. Genetic polymorphisms in transforming growth factor beta-1 (TGFβ1) and childhood asthma and atopy. Hum Genet. 2007 Jun;121(5):529-38.

18. Hur GY, Broide DH. Genes and Pathways Regulating Decline in Lung Function and Airway Remodeling in Asthma. Allergy Asthma Immunol Res. 2019 Sep;11(5):604-621. doi: 10.4168/aair.2019.11.5.604. Review.

19. Panek M, Jonakowski M, Zioło J, Wieteska Ł, Małachowska B, Pietras T, Szemraj J, Kuna P. A novel approach to understanding the role of polymorphic forms of the NR3C1 and TGF-β1 genes in the modulation of the expression of IL-5 and IL-15 mRNA in asthmatic inflammation. Mol Med Rep. 2016 Jun;13(6):4879-87.

20. Panek M, Pietras T, Fabijan A, Zioło J, Wieteska Ł, Małachowska B, Fendler W, Szemraj J, Kuna P. The NR3C1 Glucocorticoid Receptor Gene Polymorphisms May Modulate the TGF-beta mRNA Expression in Asthma Patients. Inflammation. 2015 Aug;38(4):1479-92.
21. Panek M, Pietras T, Fabijan A, Milanowski M, Witeska L, Górski P, Kuna P, Szemraj J. Effect of glucocorticoid receptor gene polymorphisms on asthma phenotypes. Exp Ther Med. 2013 Feb;5(2):572-580.

22. Panek M, Pietras T, Fabijan A, Zioło J, Witeska L, Małachowska B, Fendler W, Szemraj J, Kuna P. Identification and association of the single nucleotide polymorphisms, C-509T, C+466T and T+869C, of the TGF-β1 gene in patients with asthma and their influence on the mRNA expression level of TGF-β1. Int J Mol Med. 2014 Oct;34(4):975-86.

23. Kim WJ, Hoffman E, Reilly J, Hersh C, Demeo D, Washko G, Silverman EK. Association of COPD candidate genes with computed tomography emphysema and airway phenotypes in severe COPD. Eur Respir J. 2011 Jan;37(1):39-43.

24. National Center for Biotechnology Information (NCBI) gene database dostępna na https://www.ncbi.nlm.nih.gov/gene

25. Pietras T, Panek M, Tworek D, Oszajca K, Wujcik R, Górski P, Kuna P, Szemraj J. The Bcl I single nucleotide polymorphism of the human glucocorticoid receptor gene h-GR/NR3C1 promoter in patients with bronchial asthma: pilot study. Mol Biol Rep. 2011 Aug;38(6):3953-8.

26. Pietras T, Panek M, Kuprys-Lipinska I, Oszajca K, Wujcik R, Kuna P, Gorski P, Szemraj J. Frequencies of Bcl I, E22E, and N363S of h-GR/NR3C1 restriction fragment length polymorphisms of glucocorticoid receptor gene in Polish adult population. Med Sci Monit. 2010 Oct;16(10):CR475-9.

27. Panek M, Pietras T, Antczak A, Fabijan A, Przemęcka M, Górski P, Kuna P, Szemraj J. The N363S and I559N single nucleotide polymorphisms of the h-GR/NR3C1 gene in patients with bronchial asthma. Int J Mol Med. 2012 Jul;30(1):142-50.

28. Ding C, Peng H. Minimum redundancy feature selection from microarray gene expression data. J Bioinform Comput Biol. 2005 Apr;3(2):185-205.

29. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988 Sep;44(3):837-45.

**Supplemental Information Note**

The Supplemental File mentioned throughout the Discussion was omitted by the authors in this version of the paper.

**Figures**
Figure 1

and 1A Boxplots showing differences in the median ACT score between genotypes in selected SNPs. A detailed analysis of SNPs of TGF-β1, TGF-β2 and TGF-β3 genes potentially affecting the level of asthma control using the Kruskal-Wallis Test, p with BH correction. p - level of statistical significance. BH - Bonferroni-Hochberg correction. The authors’ own study.

Figure 2

and 2A and 2B Coefficients of the linear model for prediction of ACT score. A detailed analysis of MAC in SNPs of TGF-β1, TGF-β2 and TGF-β3 genes potentially affecting the level of asthma control using the U Mann-Whitney Test, with BH correction. p - level of statistical significance. BH - Bonferroni-Hochberg correction. The authors’ own study.
Figure 3

Multivariate linear regression analysis after stepwise backward selection of variables, describing the effect of the studied SNPs genotypes on the level of asthma control (ACT). The authors' own study.

```
## Call:
## lm(formula = ACT ~ rs8109627 + rs2799085 + rs3917187 + rs2284792,
##     data = temp)
##
## Residuals:
##     Min      1Q  Median      3Q     Max
## -18.961  -4.135   1.000   4.865   9.933
##
## Coefficients:
##                Estimate Standardized Std. Error  t value Pr(>|t|)
## (Intercept) 17.57017       0.00000    0.54900 32.004  <2e-16 ***
## rs8109627T/C 1.39051       0.11711    0.58100  2.393   0.0171 *
## rs8109627C/C -2.06833      -0.07523   1.36680 -1.513   0.1310
## rs2799085C/A -0.43472      -0.03791   0.59455 -0.731   0.4651
## rs2799085A/A 1.51001       0.08846    0.88382  1.709   0.0883 .
## rs3917187C/T 1.33525       0.11146    1.41992  0.940   0.3476
## rs3917187T/T -3.85590      -0.16262   2.71047 -1.423   0.1556
## rs2284792A/G -0.88332      -0.07489   1.40209 -0.630   0.5200
## rs2284792G/G  5.29066       0.21492    2.81947  1.876   0.0613 .
## ---
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
##
## Residual standard error: 5.628 on 411 degrees of freedom
## Multiple R-squared:  0.05858,  Adjusted R-squared:  0.0321
## F-statistic: 2.737 on 8 and 411 DF,  p-value: 0.005956
```
**Figure 4**

Analysis of ACT result prediction, depending on MAC SNPs (full analysis model including all SNPs). The authors’ own study.

```r
library(caret)
train_control <- trainControl(method="LOOCV")
model = train(ACT ~ ., data = temp, trControl=train_control, method="ctree")
plot(model$finalmodel)
```

**Figure 5**

Modeling the c-tree, allowing to prognosticate the degree of asthma control, on the basis of SNPs analysis of TGF-β1, TGF-β2 and TGF-β3 genes. The authors’ own study.

```r
postResample(pred = predict(model, newdata = temp), obs = temp$ACT)
```

| RMSE | R2squared | MAE |
|------|-----------|-----|
| 5.7144010 | NA  | 4.850726 |
Figure 6

An analysis of prognosis of effective asthma control (ACT $ \geq 25$) on the basis of ROC analysis. A Logistic regression with the application of all genotypes in SNPs contributed to AUC = 0.749. B Logistic regression with the application of all MACs in SNPs contributed to AUC = 0.661. The authors’ own study.
Figure 7

A SMOTE analysis and analysis with the application of backward stepwise selection, enabling to predict good asthma control (ACT≥ 25), on the basis of all twenty SNPs. The authors’ own study.

Figure 8

An analysis of the application of a prognostic model on the basis of SNP and MAC genotypes on the entire (training) data set for the purpose of prediction of good asthma control. The authors’ own study.